ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions
View by Date

Monday, October 22, 2018

9:00AM-11:00AM
Abstract Number: 1811
Efficacy and Safety of Interferon α2a As an Add-on Treatment for Refractory Behcet’s Uveitis
Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease
9:00AM-11:00AM
Abstract Number: 1791
Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome in a Phase III Study: A Prespecified Analysis By Baseline Patient Demographics and Disease Characteristics
Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease
9:00AM-11:00AM
Abstract Number: 1745
Efficacy of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss) Treatments According to the Type of Manifestations Based on Analysis of 376 Patients
Vasculitis – ANCA-Associated Poster I
9:00AM-11:00AM
Abstract Number: 1513
Efficacy of Etanercept By Body Mass Index in Women and Men with Rheumatoid Arthritis: A Post Hoc Analysis of Three Randomized Trials
Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity
9:00AM-11:00AM
Abstract Number: 1367
Efficacy of Intra-Articular Cntx-4975 for Knee OA Pain Varies with Radiographic Presence of OA in the Opposite Knee
Osteoarthritis – Clinical Poster II
9:00AM-11:00AM
Abstract Number: 1308
Efficacy of Rituximab for Connective Tissue Disease (CTD) Associated Interstitial Lung Disease (ILD):a Single Center Study of 47 Patients
Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis
9:00AM-11:00AM
Abstract Number: 1475
Eicosanoid Mediators of Systemic Inflammation and Arthritis in the Elderly
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis
9:00AM-11:00AM
Abstract Number: 1255
Elevated Serum Globulin Gap As a Reliable and Cost-Savings Marker of Inflammation in Patients with Systemic Rheumatic Diseases
Measures and Measurement of Healthcare Quality Poster II
9:00AM-11:00AM
Abstract Number: 1350
Elevated Serum Levels of Soluble CD146 and CD146 Autoantibody in Patients with Polymyositis/Dermatomyositis
Muscle Biology, Myositis and Myopathies Poster II: Basic and Translational Science
9:00AM-11:00AM
Abstract Number: 1499
Elevated Serum MMP-3 in Remission Predicts Relapsed in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis
9:00AM-11:00AM
Abstract Number: 993
Elucidating the Role of the Lymphatic System in the Pathogenesis of Psoriasis and Psoriatic Arthritis
Cytokines and Cell Trafficking Poster
9:00AM-11:00AM
Abstract Number: 1415
Emapalumab, an Anti-Interferon Gamma Monoclonal Antibody in Two Patients with NLRC4-Related Disease and Severe Hemophagocytic Lymphohistiocytosis (HLH)
Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous
9:00AM-11:00AM
Abstract Number: 1409
Empowerment in Hispanic Rheumatoid Arthritis Patients: A Validation Study
Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes
9:00AM-11:00AM
Abstract Number: 1094
Endogenous Ifnβ Production Is Required for Efficient BCR Crosslinking and Survival of SLE B Cells
Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II
9:00AM-11:00AM
Abstract Number: 1432
Engaging Patients and Parents to Improve Mental Health for Youth with Rheumatologic Disease
Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous
  • «Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology